Gwenn Waerlop

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine

Isabel Leroux‐Roels, Gwenn Waerlop, Jessika Tourneur et al. · Frontiers in Immunology · 2022 · 25 citations · Full text

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux‐Roels, Paul Willems, Gwenn Waerlop et al. · The Lancet Infectious Diseases · 2023 · 22 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +11

Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium

Gwenn Waerlop, Geert Leroux‐Roels, Teresa Lambe et al. · Frontiers in Immunology · 2022 · 21 citations · Full text

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Isabel Leroux‐Roels, Cathy Maes, Jasper Joye et al. · Frontiers in Immunology · 2022 · 20 citations · Full text

Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium

Sarah Begue, Gwenn Waerlop, Bruno Salaun et al. · Frontiers in Immunology · 2022 · 13 citations · Full text

Clinical Immunology, Flucop Project, Laboratory Immunology +23